Drugs / RG1-VLP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05985681 | Jan 2026 → Feb 2028 expected | carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RG1-VLP | “RG1-VLP is a vaccine that aims to protect against rare HPV types not targeted by currently approved HPV vaccines.” NCT05985681 ↗ |
| Modality | Vaccine | “RG1-VLP is a vaccine” NCT05985681 ↗ |
| Route | Intramuscular | “Patients receive RG1-VLP intramuscularly (IM)” NCT05985681 ↗ |